Gutseer®

Introducing GutSeer®, a groundbreaking noninvasive test revolutionizing the early detection and localization of gastrointestinal (GI) cancers. GutSeer® offers cost-effective blood-based assay leveraging cell-free DNA (cfDNA) methylation and fragmentation signatures. Our innovative approach relies on a single targeted DNA methylation sequencing panel, comprising 1656 target regions, designed for early detection across five major GI cancers: colorectal (CC), gastric (GC), liver (LC), esophageal (EC), and pancreatic cancer (PC).